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Abstract
Background:  An estimated 2–3 million people are acutely poisoned by organophosphorus
pesticides each year, mostly in the developing world. There is a pressing need for new affordable
antidotes and clonidine has been shown to be effective in animal studies. Our aim was to determine
the safety of clonidine given as an antidote in adult patients presenting with signs or symptoms of
acute organophosphate ingestion.
Methods: This study was a dose finding, open-label, multicentre, phase II trial. Forty eight patients
with acute organophosphate poisoning were randomized to receive either clonidine or placebo:
Four to receive placebo and twelve to receive clonidine at each dose level. The first dose level was
an initial loading dose of 0.15 mg followed by an infusion of 0.5 mg of clonidine over 24 hours. The
initial loading dose was increased to 0.3 mg, 0.45 and 0.6 mg. at all dosing levels however the
subsequent infusion remained at 0.5 mg of clonidine over 24 hours.
Results: The baseline characteristics of both groups were similar. The trial was stopped after
completion of the 3rd dosing level. At the 1st and 2nd dosing level there were no reported adverse
drug reactions. At the 3rd dosing level 5 patients (42%) developed significant hypotension during
clonidine treatment that responded to intravenous fluids. There were no statistical differences in
ventilation rate, pre and post GCS, and mortality rates over all levels.
Conclusion: Our findings suggest use of moderate doses of clonidine in acute organophosphate
poisoning can be used without causing frequent clinical problems but that higher doses are
associated with a high incidence of hypotension requiring intervention. Further studies are needed
to study the efficacy of clonidine as an antidote in organophosphate poisoning.
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Background
Each year at least 300,000 thousand people die from
deliberate ingestion of pesticides [1]. These deaths are
responsible for about a third of the global burden of ill-
ness from suicide [2]. In many countries this is the leading
cause of lives lost in early to middle adult life. Anti-
cholinesterase pesticides account for two thirds of these
pesticide poisoning deaths and these are most common in
rural areas of the developing world where the World
Health Organization (WHO) estimates 2–3 million peo-
ple are affected annually. In Asia alone 200,000 deaths per
year result from intentional ingestion of organophospho-
rus (OP) compounds; poisoning has an estimated case
fatality of between 5 and 30% [3]. Poisoning in Sri Lanka
is always among the five leading causes of mortality and
morbidity and accounts for about 80,000 hospitalizations
and 3000 deaths per year [4]. This problem is com-
pounded by the fact that approximately 35% of patients
acutely poisoned with organophosphates require inten-
sive care and mechanical ventilation [5]. This is despite
conventional antidote treatment with atropine and pral-
idoxime [3]. One reason for this high mortality is the fail-
ure of pralidoxime to be effective in many clinical
situations. The major mechanism of toxicity from organo-
phosphorus pesticides is inhibition of the synaptic acetyl-
cholinesterase enzyme. Acetylcholinesterase inhibition is
initially reversible but eventually becomes irreversible, a
process which is commonly termed "ageing". Acetylcho-
linesterase inhibition leads to excessive accumulation of
acetylcholine at nicotinic and muscarinic synapses lead-
ing to widespread clinical effects culminating in neu-
romuscular and respiratory failure.
Acute respiratory failure leading to death is a major clini-
cal problem in OP poisoning. In one study involving 376
patients intoxicated with OP, 90 (24%) required intuba-
tion and ventilatory support during their hospital admis-
sion. Forty-six (51%) of the intubated patients died[6].
Acute respiratory failure produced by cholinesterase
inhibitors is mainly due to inhibition of central respira-
tory drive and direct pulmonary toxicity [7]. Atropine is
effective at competitively blocking the effects of acetylcho-
line at the muscarinic receptor. Oximes, such as pralidox-
ime, can reactivate acetylcholinesterase but the ability to
reverse acetylcholinesterase (AChE) inhibition with oxi-
mes varies with the type of pesticide ingested and time to
treatment as both these factors affect the rate of enzyme
ageing [8,9]. Moreover, as pralidoxime has poor CNS pen-
etration its effects are largely restricted to the peripheral
nervous system. In Sri Lanka and much of rural Asia,
delays in initiating treatment and the use of organophos-
phates that are associated with rapid ageing of acetylcho-
linesterase inhibition contribute significantly to treatment
failure with pralidoxime. This treatment failure also con-
tributes to a high treatment cost as pralidoxime is rela-
tively expensive [10].
In this clinical setting it is appropriate to examine inex-
pensive antidotes operating through synergistic mecha-
nisms that are not dependent upon acetylcholinesterase
reactivation. One approach is to reduce the amount of
acetylcholine released into the synapse.
Clonidine, a centrally acting antihypertensive agent, is
known to decrease the presynaptic synthesis and release of
acetylcholine. This pre-synaptic effect is greater in the cen-
tral nervous system than in peripheral cholinergic syn-
apses [11]. Administration of clonidine to animals
poisoned with organophosphorus pesticides has been
shown to improve outcome in numerous studies [12-16].
Other studies found that both atropine and clonidine in
OP-intoxicated mice showed increased survival time with
delay in development of whole body tremor and loss of
righting reflex [17] and reduced salivation [18]. Doses of
0.3 and 1.0 mg/kg were both effective in reducing mortal-
ity from soman (1/7 deaths vs 14/16 in controls) [14]. In
a study that explored a wider range of doses (between
0.125 and 8 mg/kg IM) in rats poisoned with soman, the
optimal doses in reducing mortality were 0.5 and 1.0 mg/
kg. Adverse effects were markedly more obvious at doses
greater than 0.5 mg/kg but minor at that dose and below
[16]. A dose of 0.5 mg/kg was highly effective in soman
poisoning but a dose of 0.2 mg/kg when combined with a
sub-therapeutic dose of atropine was as effective as 0.5
mg/kg [19]. This suggests an additive or synergistic effect
of clonidine with atropine. Lower doses may therefore
have the optimal balance of risks and benefits in clinical
practice [12].
Clonidine was shown to be ineffective against echothio-
pate, an organophosphorus pesticide that does not enter
or have effects on the central nervous system. Therefore, it
is likely the antidotal effect of clonidine is predominately
centrally mediated [14]. This may indicate there will be
further clinical benefit over current antidotes as OP-
induced centrally mediated respiratory failure is unlikely
to respond to oximes and is likely to involve non-mus-
carinic receptors that are not blocked by atropine. Cloni-
dine may also inhibit the release of inflammatory
neuropeptides that may be involved in pulmonary toxic-
ity [20].
Clonidine has been used widely in humans for decades.
Most commonly, it has been used for the treatment of
high blood pressure (particularly in pregnancy), opioid
withdrawal, and sedation in intensive care. The pharma-
cological mechanism involves blockade of central alpha-
2-adrenergic receptors. The most frequent adverse effectsTrials 2009, 10:73 http://www.trialsjournal.com/content/10/1/73
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are low blood pressure and sedation, but these effects are
generally not serious or life-threatening. The typical doses
used in narcotic withdrawal and hypertension are
between 0.15 mg to 0.3 mg four times daily. Higher doses
are used intravenously for sedation: – a bolus of 0.0015 to
0.005 mg/kg (up to a maximum of 0.6 mg) and then an
infusion of 0.0003 mg/kg/h [21]. These routinely used
sedating intravenous doses informed the choice of doses
explored within this trial.
Our aim was to explore the effect of a range of doses of
clonidine, primarily to look at which doses were well tol-
erated in patients with OP poisoning.
Methods
Trial Design and Study Population
The study was planned as an open-label Phase II progres-
sive dose-ranging study with four doses explored in stages.
Sequential groups of 16 patients were randomized to
receive either a bolus dose of clonidine in a stage-wise
manner (0.15, 0.30, 0.45, or 0.6 mg) and then a constant
0.5 mg clonidine/24 hours or to receive a glucose infusion
at every level (Figure 1). After written informed consent
was obtained, randomization was performed centrally by
a computer-generated randomization program that ran-
domly assigned subjects within each dose cohort to active-
drug or placebo treatment in a 3:1 ratio. Thus, at each
treatment level, twelve subjects were to receive clonidine
and four were controls. Although the patients were
blinded, the treating physician, nurses and clinical
research assistants were aware of the treatment allocation.
The patients were recruited between May 2006 and May
2008 at the Chilaw and Polonnaruwa General hospitals in
rural Sri Lanka. Subjects were recruited who had sympto-
matic acute OP poisoning. Eligibility required a history of
OP pesticide ingestion and cholinergic features and/or
prior administration of atropine for such features. Where
possible, the specific type of OP pesticide ingested was
confirmed by identification of the brand name or exami-
nation of the bottle. Pregnant patients and those younger
than 16 years of age were excluded. Subjects were also
excluded if they were hypotensive (BP <90/50 mmHg) on
presentation, if they ingested other substances in addition
to OP pesticide, or if they had other serious medical con-
ditions (e.g. cardiovascular disease, renal or hepatic fail-
ure). Other than study medication, patients received
standard medical care under the hospital's admitting con-
sultant physician. This usually included titrated doses of
atropine and pralidoxime chloride 1 gram 6th hourly for
48 hours.
The study received ethical approval from the Sri Lanka
Medical Association (ERC/05-008), and the Australian
National University Human Research Ethics Committees
(2005/159). It was registered with the International Trial
Registry Number ISRCTN89917816.
Dosing Regimen
Catapress® – clonidine 150 ug/ml batch number 526088c
produced by Boehringer Ingelheim, New South Wales,
Australia was used. The initial loading dose (0.15 mg, 0.3
mg, or 0.45 mg) was given over 10 minutes diluted to 10
ml normal saline. At all dose levels an infusion of 0.5 mg
of clonidine was then diluted in 500 ml of 5% dextrose
and given over 24 hours with infusion pumps. 'Placebo'
loading doses and infusions were an equal volume of 5%
dextrose. Drugs were prepared shortly before use by a reg-
istered pharmacist.
Assessment of Outcomes
All patients were prospectively monitored with regular
measurement of their pulse, BP and saturation via a bed-
side vital signs monitor by medically qualified and trained
research assistants. They also recorded patient demo-
graphics, the type and amount of organophosphate, alco-
hol co-ingestion and other co-morbid conditions and
recorded the occurrence of specific clinical outcomes:
death, ventilation, hypotension (BP <80/40), and adverse
reactions to clonidine. The doses of atropine prior to, dur-
ing and after clonidine treatment were also recorded.
The trial was an exploratory dose-finding phase II study to
guide safe dosing in subsequent larger studies. Therefore
it had a low power to detect differences in major clinical
outcomes and any therapeutic efficacy. No formal sample
size or power calculation was performed. The specified
primary outcome measure was the proportion of patients
in each of the randomized group levels who either were
ventilated or died. Secondary outcome measures included
decreased level of consciousness and hypotension defined
by a manual blood pressure reading of equal to or less
than 80/40 mmHg. The change in heart rate and blood
pressure and the requirements for atropine over the 24
hours of clonidine of treatment were also compared.
Data Analysis
Analysis of major clinical outcomes was done on all rand-
omized patients based upon intention to treat. All
patients who were randomised were included in the anal-
ysis. As management protocols did not change over the
course of the study patients randomised to placebo at
each dose level were aggregated into one group to facili-
tate an examination for adverse effects.
Statistical analysis was performed using STATA v8 and
Prism V5. Clinical characteristics were summarized using
counts (percentages) for categorical data and median
(interquartile range [IQR]) for non-normally distributed
continuous variables. The data on age, amount of poisonTrials 2009, 10:73 http://www.trialsjournal.com/content/10/1/73
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Trial flowchart Figure 1
Trial flowchart.
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ingested and atropine dosing were analyzed using the
Kruskal Wallis test. Thereafter Dunn's test was used when-
ever an overall difference was noted. Proportions were
compared with the Chi square test. Two-way repeated
measures ANOVA and whenever appropriate Bonferroni
post hoc pair-wise comparison was done to compare
blood pressure readings over the entire 24 hours.
Results
Between May 2006 and May 2008 we recruited 48 symp-
tomatic acute OP pesticide poisoning cases from two
peripheral hospitals in rural Sri Lanka. One patient died
just after randomization prior to clonidine treatment
while thirty-five received the initial doses of the active
drug (0.15 mg, 0.3 mg or 0.45 mg) and 12 study subjects
received a placebo. At the 3rd dosing level, low blood pres-
sure readings (<80/40) were recorded in 5/11 patients
during infusions; therefore, the trial was stopped before
proceeding to the cohort at the highest planned dose (0.6
mg bolus).
The baseline characteristics and the time to start placebo
or treatment were reasonably balanced across all groups
(table 1). It is worth noting that more patients in the pla-
cebo arm had ingested chlorpyrifos (7; 58%), while in the
3rd dosing level there were a much higher number of
dimethoate ingestions (7; 58%). This related to a change
in the most common OP ingested (Figure 1). There were
three deaths; two of these were dimethoate poisonings
while the other had ingested quinalphos. All developed
hypotension and respiratory failure requiring ventilator
support prior to death.
The atropine doses were similar with respect to bolus
doses and there was a statistically significant difference
between groups in the infusion rates due to higher pre-
infusion atropine doses in the 3rd vs. 2nd dosing levels
(Dunn's test, P < 0.05) (Table 2). The total atropine dura-
tion was similar across all groups.
There was no statistical difference in primary clinical out-
comes analyzed based on intention to treat (i.e. included
the patient who died prior to receiving clonidine) (Table
3). However, at the third (highest) dosing level, 4 (33%)
patients were ventilated and 3 deaths occurred, all in ven-
tilated patients. One patient (9%) developed a single epi-
sode of sinus pauses less than 3 seconds in duration 6
hours after commencing the infusion. The infusion was
stopped thereafter in this patient.
The third dosing level also had a statistically higher (p <
0.001) incidence of hypotension; five (45%) of the 11
patients who received clonidine developed hypotension
(BP <80/40) at some stage. The clonidine in these 5
patients was temporarily discontinued at this time. In
these patients the lowest recorded blood pressure was 71/
53 mmHg. All five had some decrease in systolic, diastolic
and mean arterial pressure within the first hour of infu-
sion but lowest values were delayed toward the middle of
the infusion. They all returned to normal range with intra-
venous fluids (20 ml/kg rapid bolus) within approxi-
mately 60 minutes without any sequelae.
In contrast, the lower two doses were well tolerated,
although statistically significant effects on blood pressure
Table 1: Baseline Characteristics according to randomized treatment with clonidine.
Dosing Level
Placebo Level 1 Level 2 Level 3 P Value
n = 12 n = 12 n = 12 n = 12†
Males 10 (83%) 11 (91%) 10 (83%) 9 (75%) 0.75
Age (years)* 32 (23–47) 31 (26–38) 26 (22–34) 37 (31–46) 0.2
Amount of poison ingested (mL)* 60 (50–100) 55 (50–100) 50 (30–80) 80 (35–100) 0.64
Time to admission after ingestion (hrs)* 3.5 (3–6) 5(1–7) 4 (3–7) 3 (3–3) 0.58
Time to start clonidine from ingestion (hrs)* 6 (3–7) 6 (4–9) 6(5–8) 5 (4–5) 0.41
Direct admission 4 (33%) 5 (42%) 4 (33%) 5 (42%) 0.95
Alcohol ingestion 5(42%) 2(17%) 4(33%) 6(50%) 0.28
Co-Morbid Illness€ 0 (0%) 2(17%) 1(8%) 2(17%) 0.59
Pralidoxime used 4 (33%) 7 (58%) 5 (42%) 2 (17%) 0.25
Pesticide:
Chlorpyrifos 7 (58%) 3(25%) 4 (33%) 0 (0%) 0.018£
Dimethoate 0 (0%) 1 (8%) 1 (8%) 7 (58%) 0.001¥
Others≠ 5 (42%) 8 (67%) 7(58%) 5 (42%)
Data are number (%) unless otherwise indicated. *Median (IQR).). †One patient died after randomization before receiving clonidine. Comparisons 
between the three groups were made using a Kruskal-Wallis. £P < 0.05 by Kruskal-Wallis with post hoc Dunn's test between level 1 and placebo. ¥P 
< 0.05 by Kruskal-Wallis with post hoc Dunn's test between level 3 and placebo. €Co-morbid illness included cardiac, pulmonary, psychiatric, 
neurologic and undiagnosed disorders. ≠Diazinon, Phenthoate, Profenophos, Monocrotophos, Fenthion, Quinalphos.Trials 2009, 10:73 http://www.trialsjournal.com/content/10/1/73
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were noted (Figure 2). The mortality and need for ventila-
tion was (non-significantly) lower than in the placebo
group, as were atropine doses. No important adverse drug
events were recorded.
There was a statistically significant higher rate of mean
observed blood pressure recordings in the active groups
(8.3 ± 2.6 vs 4.9 ± 1.4; p < 0.001).
Figure 2 shows the pattern of systolic, diastolic and mean
arterial pressures in all cohorts. There was no statistically
significant effect of treatment on systolic blood pressure
of the treatment group when compared to the placebo
arm (two-way repeated measures ANOVA with Bonferroni
posttest). The second dosing level showed a statistically
significant lower mean arterial pressure which occurred 3
and 5 hours (p < 0.05) into the infusion. The third dosing
level showed statistically significant lower diastolic pres-
sure at 40 minutes and a significantly lower mean arterial
pressure at 20 & 40 minutes and at 5 hours post the load-
ing dose during the infusion (p < 0.05). The maximum
decrease from baseline in systolic blood pressure, diasto-
lic pressure and mean arterial pressures ranged from 30 to
57 mmHg, 21 to 40 mmHg and 23 to 38 mmHg respec-
tively across all clonidine doses (Table 4).
Discussion
Clonidine has been studied extensively in the past and has
been used widely in humans for decades. The pharmaco-
logical mechanism involves blockade of central alpha-2-
adrenergic receptors and imidazoline receptors [22]. The
most frequent adverse effects are low blood pressure and
sedation.
Hypotension was the most frequently observed event.
There were small decreases in mean blood pressure at all
doses. At the third dosing level the hypotension required
treatment with fluid boluses and temporary stoppage of
the infusion; the blood pressure thereafter returned to
normal after 15 to 30 minutes. None of these patients
required vasopressor support; however, the investigators
decided that there was a low likelihood that higher doses
would be well accepted by the treating staff and the trial
was ceased at this time. A dose in the order of 0.15 or 0.3
mg clonidine bolus and 0.5 mg/24 h infusion appears
most likely to be clinically acceptable for further studies in
this low-resource setting.
The episodes of hypotension may simply be explained by
the larger doses of clonidine, but other factors may have
contributed. The acute effects of organophosphorus pesti-
Table 2: Atropine Doses in RCT pre and post commencement of the clonidine infusion.
Placebo Level 1 Level 2 Level 3 P value
n = 12 n = 12 n = 12 n = 12†
Pre clonidine dosing
Atropine Bolus (mg) 9 (2–28) 6 (1–12) 2 (1–6) 6 (3–24) 0.19
Atropine Infusion (mg/hour) 10 (1–24) 1 (1–1) 1 (1-1) 5 (1–11) 0.008£
Post clonidine dosing
Atropine Bolus (mg) 6 (2–9) 1 (0–1) 0(0–3) 1 (1–15) 0.05
Atropine Infusion (mg/hour) 2 (0–16) 1 (1-1) 1 (0–2) 6 (1–15) 0.47
Data are Median (IQR); †One patient died after randomization before receiving clonidine. Comparisons between the three groups were made using 
a Kruskal-Wallis.£P < 0.05 by Kruskal-Wallis with post hoc Dunn's test between level 2 and level 3 groups.
Table 3: Clinical outcomes according to randomized allocation of clonidine treatment (ITT).
Placebo Level 1 Level 2 Level 3 P value
n = 12 n = 12 n = 12 n = 12†
GCS < 15
Pre Intervention 7(58%) [30 to 83] 4(33%) [12 to 62] 7(58%) [30 to 83] 5(41%) [17 to 70] 0.52
Post Intervention 5(42%) [17 to 70] 3(25%) [7 to 54] 5(42%) [17 to 70] 6(50%) [23 to 77] 0.64
GCS ≤ 8
Pre Intervention 2(17%) [3 to 45] 0(0%) [0 to 22] 1(8%) [0.4 to 35] 1(8%) [0.4 to 35] 0.53
Post Intervention 1(8%) [0.4 to 35] 1(8%) [0.4 to 35] 1(8%) [0.4 to 35] 2(17%) [3 to 45] 0.88
Hypotension* 0(0%) [0 to 22] 0(0%) [0 to 22] 0(0%) [0 to 22] 6(50%) [23 to 77] <0.001£
Ventilation 4(33%) [12 to 62] 3(25%) [7 to 54] 0(0%) [0 to 22] 4(33%) [12 to 62] 0.17
Death 1(8%) [0.4 to 35] 0(0%) [0 to 22] 0(0%) [0 to 22] 3(25%) [7 to 54] 0.08
Ventilated or death 4(33%) [12 to 62] 3(25%) [7 to 54] 0(0%) [0 to 22] 4(33%) [12 to 62] 0.17
Data are in n (%) [95% CI];*Blood pressure less than 80/40 mmHg. †One patient died after randomization before receiving clonidine. £P < 0.05 by 
Kruskal-Wallis with post hoc Dunn's test between level 3 and placebo.Trials 2009, 10:73 http://www.trialsjournal.com/content/10/1/73
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Time course of (A) systolic, (B) diastolic and (C) mean arterial pressure (MAP) changes in placebo group (n = 12), level 1 (n =  12), level 2 (n = 12) and level 3 (n = 11) treatment groups in 24 hours Figure 2
Time course of (A) systolic, (B) diastolic and (C) mean arterial pressure (MAP) changes in placebo group (n = 
12), level 1 (n = 12), level 2 (n = 12) and level 3 (n = 11) treatment groups in 24 hours. Note that in five patients at 
level 3, the clonidine was stopped at some stage because of hypotension (BP <80/40 mmHg) and patients were given extra flu-
ids. Two-way ANOVA showed significant differences between clonidine doses in diastolic blood pressure (effect of treatment: 
F = 5.40, df = 3, P < 0.05; time post randomization: F = 1.31, df = 15, P > 0.05) and mean arterial pressure (effect of treatment: 
F = 5.62, df = 3, P < 0.05; time post randomization: F = 1.01, df = 15, P > 0.05) but not in the systolic blood pressure (effect of 
treatment: F = 2.46, df = 3, P > 0.05; time post randomization: F = 1.02, df = 15, P > 0.05). The Bonferroni post-test was also 
significant at the asterixed data points vs placebo (P < 0.05).
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cide include hypotension. This is much more common
with dimethoate poisoning, which also has a higher case-
fatality (23%) than chlorpyrifos (8%) or fenthion
(16%)[8]. Seven (58%) of the 12 patients who had
received the highest dose had ingested dimethoate; 5 of
these were either unconsciousness, hypotensive and/or
required intensive care treatment and this may account for
the higher death rate (3/12;25%) at this level. Other
aggravating factors, such as gastrointestinal decontamina-
tion procedures or persistent vomiting and diarrhea, may
also lead to volume depletion. This highest dose group
also had the lowest use of pralidoxime. Pralidoxime is
known to increase blood pressure and this may also have
contributed to lower blood pressures in this group.
The sedative effects of clonidine are attributed to activa-
tion of the alpha-2-adrenergic receptor in the locus coeru-
leus which suppresses the spontaneous firing rate of the
nucleus and increases the activity of GABA[23]. Sedation
was not pronounced in our patients. Clonidine in the set-
ting of OP poisoning may possibly be less sedating as ace-
tylcholine is a CNS stimulant.
Other than hypotension no other important adverse drug
events occurred. One patient in the high clonidine dose
group had a brief (less than 3 sec) sinus pause recorded
which might have been related to clonidine. Although
dysrhythmia associated with clonidine is rare[22], there
have been a few case reports of AV block and cardiac dys-
rhythmia [24,25]; these occurred in conjunction with
other substances also reported to cause such effects mak-
ing causality difficult to establish. Similarly, for our
patient, dysrhythmia have been observed with OP poison-
ing alone.
We found no significant difference in the primary out-
come measure of 'ventilation or death' all of which
occurred post-treatment. This was not surprising as
although this was our pre-specified primary outcome, our
trial was inadequately powered to detect anything but an
extreme difference in this outcome. While not statistically
significant, the first two doses were well tolerated and
associated with better than average outcomes; the case-
fatality within the trial (8%) was lower than the overall
case fatality of 20% [26] for acute symptomatic organo-
phosphorus pesticide poisoning.
Our study had three main limitations. The most impor-
tant is that it was small and designed to guide future stud-
ies rather than powered to reach definitive conclusions. It
was also an open-label trial. This was required to address
concerns on the hypotensive effect of clonidine raised by
the attending physicians and ward staff. Thus, knowledge
of treatment allocation by the treating physician might
have influenced monitoring and treatment decisions. For
example, blood pressure was measured twice as frequently
in the active arms as compared to the placebo arm. This
may have lead to a bias towards more frequent detection
of low blood pressure in the treatment arms. Third, there
was not random allocation between different doses (only
between placebo and a particular dose). This led to sub-
stantive baseline imbalances between clonidine dose lev-
els in the OP taken, probably due to seasonal variation in
patterns of pesticide use (Figure 1). The greater number of
severely unwell patients into the highest dose cohort may
also be due to the ward staff being more confident in
recruiting such patients as the trial progressed.
Thus it is inappropriate to interpret the results of this trial
in isolation. Its primary purpose was to determine if larger
more definitive trials can be ethically justified. The sec-
ondary purpose was to provide data relevant to the design
of further trials.
Conclusion
In our limited pilot study clonidine was well tolerated at
the two lowest dosing levels suggesting that moderate
doses of clonidine (150 μg or 300 μg bolus and 500 μg/24
Table 4: Effect of treatment on the maximum change in systolic, diastolic and mean arterial blood pressure.
Treatment arm Placebo (n = 12) Level 1 (n = 12) Level 2 (n = 12) Level 3 (n = 11)
Systolic blood pressure
Baseline mean (SD) 116(16) 125(9) 123(26) 122(15)
Maximum change -36 -30 -57 -32
Minimum change 0 0 1 1
Diastolic blood pressure
Baseline mean (SD) 75(9) 77(11) 80(16) 76(17)
Maximum change -21 -24 -28 -40
Minimum change 1 1 0 0
Mean arterial pressure
Baseline mean (SD) 88(10) 93(9) 95(18) 91(16)
Maximum change -25 -23 -35 -38
Minimum change 0 0 0 0Trials 2009, 10:73 http://www.trialsjournal.com/content/10/1/73
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hours) in acute organophosphate poisoning can be used
without causing frequent clinical problems in resource-
poor settings. Together with the extensive previous data
on the safety of clonidine, our study suggests that cloni-
dine has an acceptable safety profile at these doses when
used in this setting. Reassuring in terms of safety, clinical
outcomes in the lower dose groups were also (non-signif-
icantly) better than in the control group and in historical
controls. These safety data should be interpreted with
respect to the current high mortality from acute OP poi-
soning with standard treatment and the favorable data
from animal studies on clonidine. We believe the data
provide a basis to support further larger trials of clonidine
to evaluate efficacy and gather further safety data.
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